Annotated Bibliography On Bedrails

COMMENTARY

11 Hospital Bed Safety Workgroup. Clinical guidance for the assessment and implementation of bed rails in hospitals, long term care facilities, and home care settings. April, 2003: http://www.ahca.org/quality/ bedrails0304.pdf (accessed Nov 17, 2003). 12 Hoffman S, Powell-Cope G, Rathvon L, et al. BedSAFE: Bed safety alternatives for frail elders. http://www.patientsafetycenter.com/ BedSAFE%20for%20best%20practices_5.ppt (accessed Nov 17, 2003). 13 Hanger HC, Ball MC, Wood LA. An analysis of falls in the hospital: can we do without bedrails? J Am Geriatr Soc 1999; 47: 529–31. 14 Myint S, Neufeld R, Dunbar J. Removal of bedrails on a short-term nursing home rehabilitation unit. Gerontologist 1999; 39: 611–14.

Highs and lows…show more content…
Then it was announced that the police would not be bothering too much about the discreet social use of cannabis after its UK classification was relaxed from class B to C. Of course, the official government line remained that the drug is both illegal and dangerous. The inconsistency and confusion is on a global scale as different countries struggle to apply the 1961 UN Single Convention to 21st century reality—or wriggle to ignore it. Booth claims that UN action was driven in part by the first commissioner of the US Federal Bureau of Narcotics and also by the absence of evidence that cannabis had any medical value. When the USA ratified the Single Convention in 1967, Bureau chief Harry J Anslinger’s “intolerant reign of disinformation and prejudice” was over but he still had a strong influence on UN thinking. Booth suggests that, historically, US policy on cannabis was influenced by pressure from petrochemical and paper companies afraid of hemp as a competitor. This prolific plant has many uses. More worryingly, though without offering evidence, he accuses…show more content…
By Martin Booth. London: Doubleday/ Transworld, 2003, Pp 354, ISBN 0385 603045, £16.99. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611–16. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003; 2: 291–98. Zajicek J, Fox P, Sanders H, on behalf of the UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebocontrolled trial. Lancet 2003; 362: 1517–26. Bussy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169–72. Dyer G. Cannabis: an evil weed or a pot of gold? Financial Times Oct 17, 2003: 15. Pertwee RG, Ross RA. Cannabis receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101–21. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252–70. Degenhardt L, Hall W. Cannabis and psychosis. Curr Psychiatry Rep 2002; 4: 191–96. Arsenault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212–13. Boggan S. If cannabis is safe, why am I a psychotic? Times (London) Jan 7, 2004: T2, 4–5. Degenhardt L, Hall W, Lynskey M. Testing the hypothesis about the relationship between cannabis use and psychosis. Drug